Trial Profile
A retrospective study assessing efficacy of enzalutamide or abiraterone as a first line therapy in patients with metastatic castration-resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 12 Aug 2016 New trial record